PHILADELPHIA, May 17 – Many proteomics companies are promising more than they can deliver because they don’t yet have the technology to isolate and characterize low abundance proteins, Ian Humphery-Smith, a protein chemist at the University of Utrecht and the organizer of the Human Proteome Organization, said Thursday.

While companies, such as Large Scale Biology and Myriad, have touted the ability of their technology to pick out most of the proteins in certain cells, they haven’t identified more than five percent of the proteins in the human body, Humphery-Smith said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.